

Surgical Site Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S23211054A2BEN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: S23211054A2BEN

Abstracts

The 7 major surgical site infections markets reached a value of US\$ 664.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,174.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2024-2034.

The surgical site infections market has been comprehensively analyzed in IMARC's new report titled "Surgical Site Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Surgical site infections (SSI) refer to a medical condition that arises after surgery in the area of the body where the procedure was conducted. It mainly occurs due to the colonization of a surgical incision by infectious agents, such as bacteria or fungi. SSI can either be superficial, simply affecting the skin, or more serious, affecting organs, implanted materials, or tissues beneath the skin. The disease symptoms usually manifest within thirty days of a surgical operation. Some of the common indications associated with this illness include redness, pain, fever, delayed healing, tenderness, swelling, etc. Individuals suffering from the condition may also experience drainage of cloudy fluid or pus from the wound site. The diagnosis of surgical site infections typically requires a combination of the patient's medical history, clinical features, and laboratory studies. The healthcare provider may also collect a wound swab to determine the presence of disease-causing microorganisms. Additionally, ultrasonography, which can detect abscesses within a surgical site and regulate their drainage, is utilized to confirm a diagnosis among patients.

The increasing cases of endogenous and exogenous infections caused by contamination of the operative site by microorganisms during the procedure are primarily driving the surgical site infections market. In addition to this, the rising

incidence of various risk factors, including increased length of surgical duration, a weakened immune system, certain co-morbidities like diabetes and cancer, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antibiotic drugs, such as cefazolin, metronidazole, vancomycin, clindamycin, etc., for treating the ailment is acting as another significant growth-inducing factor. These medications prevent disease progression by destroying or slowing the proliferation of microorganisms causing the infection, thereby helping to promote wound healing. Additionally, several government bodies and non-governmental organizations are supporting numerous health education campaigns to create general awareness about preventive measures, the benefits of early diagnosis, and treatment alternatives for SSI. This, in turn, is further creating a positive outlook for the market. Moreover, the emerging popularity of combination therapy involving nasal mupirocin and a chlorhexidine body wash, since they can optimally decolonize patients with bacterial growth and reduce the risk of microbial contamination, is expected to drive the surgical site infections market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the surgical site infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for surgical site infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the surgical site infections market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the surgical site infections market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the surgical site infections market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current surgical site infections marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the surgical site infections market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the surgical site infections market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the surgical site infections market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of surgical site infections across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of surgical site infections by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of surgical site infections by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with surgical site infections across the seven major markets?

What is the size of the surgical site infections patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of surgical site infections?

What will be the growth rate of patients across the seven major markets?

Surgical Site Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for surgical site infections drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the surgical site infections market?

What are the key regulatory events related to the surgical site infections market?

What is the structure of clinical trial landscape by status related to the surgical site infections market?

What is the structure of clinical trial landscape by phase related to the surgical site infections market?

What is the structure of clinical trial landscape by route of administration related to the surgical site infections market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SURGICAL SITE INFECTIONS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

5 SURGICAL SITE INFECTIONS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 SURGICAL SITE INFECTIONS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (?2018-2023?)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8.1 Epidemiology Scenario (?2018-2023?)
- 7.8.2 Epidemiology Forecast (?2024-2034?)
- 7.8.3 Epidemiology by Age (?2018-2034?)
- 7.8.4 Epidemiology by Gender (?2018-2034?)
- 7.8.5 Diagnosed Cases (?2018-2034?)
- 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 SURGICAL SITE INFECTIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 SURGICAL SITE INFECTIONS - UNMET NEEDS

10 SURGICAL SITE INFECTIONS - KEY ENDPOINTS OF TREATMENT

11 SURGICAL SITE INFECTIONS - MARKETED PRODUCTS

- 11.1 List of Surgical Site Infections Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 SURGICAL SITE INFECTIONS - PIPELINE DRUGS

12.1 List of Surgical Site Infections Pipeline Drugs Across the Top 7 Markets

12.1.1 D PLEX - Polypid

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 XF 73 - Destiny Pharma

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 E 101 - Exoxemis

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. SURGICAL SITE INFECTIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SURGICAL SITE INFECTIONS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 SURGICAL SITE INFECTIONS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Surgical Site Infections - Market Size

15.2.1.1 Market Size (?2018-2023?)

- 15.2.1.2 Market Forecast (?2024-2034?)
- 15.2.2 Surgical Site Infections - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (?2018-2023?)
 - 15.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3 Market Scenario - United States
 - 15.3.1 Surgical Site Infections - Market Size
 - 15.3.1.1 Market Size (?2018-2023?)
 - 15.3.1.2 Market Forecast (?2024-2034?)
 - 15.3.2 Surgical Site Infections - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (?2018-2023?)
 - 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.3.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Surgical Site Infections - Market Size
 - 15.4.1.1 Market Size (?2018-2023?)
 - 15.4.1.2 Market Forecast (?2024-2034?)
 - 15.4.2 Surgical Site Infections - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (?2018-2023?)
 - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.4.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Surgical Site Infections - Market Size
 - 15.5.1.1 Market Size (?2018-2023?)
 - 15.5.1.2 Market Forecast (?2024-2034?)
 - 15.5.2 Surgical Site Infections - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (?2018-2023?)
 - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.5.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Surgical Site Infections - Market Size
 - 15.6.1.1 Market Size (?2018-2023?)
 - 15.6.1.2 Market Forecast (?2024-2034?)
 - 15.6.2 Surgical Site Infections - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (?2018-2023?)
 - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.6.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Surgical Site Infections - Market Size
 - 15.7.1.1 Market Size (?2018-2023?)

- 15.7.1.2 Market Forecast (?2024-2034?)
- 15.7.2 Surgical Site Infections - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (?2018-2023?)
 - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.7.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Surgical Site Infections - Market Size
 - 15.8.1.1 Market Size (?2018-2023?)
 - 15.8.1.2 Market Forecast (?2024-2034?)
 - 15.8.2 Surgical Site Infections - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (?2018-2023?)
 - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.8.3 Surgical Site Infections - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Surgical Site Infections - Market Size
 - 15.9.1.1 Market Size (?2018-2023?)
 - 15.9.1.2 Market Forecast (?2024-2034?)
 - 15.9.2 Surgical Site Infections - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (?2018-2023?)
 - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.9.3 Surgical Site Infections - Access and Reimbursement Overview

16 SURGICAL SITE INFECTIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SURGICAL SITE INFECTIONS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 SURGICAL SITE INFECTIONS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Surgical Site Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S23211054A2BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S23211054A2BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

